Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB TrialNancy U. Lin, Eric P. Winer, Philippe L. Bédard et al.|Journal of Clinical Oncology|2020Cited by 556
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesNancy U. Lin, Eric P. Winer, Rashmi K. Murthy et al.|JAMA Oncology|2022Cited by 205
Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinationsDebbie C. Koay, Michael P. DiGiovanna|Breast Cancer Research|2010Cited by 59
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).Nancy U. Lin, Eric P. Winer, Rashmi K. Murthy et al.|Journal of Clinical Oncology|2020Cited by 12
Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)Nancy U. Lin, Eric P. Winer, Rashmi K. Murthy et al.|Cancer Research|2022Cited by 7